NASDAQ:TCDATricida Stock Price, Forecast & News

$26.10

+0.11 (+0.42 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$25.99

Now: $26.10▼

$27.77

50-Day Range

$26.36

MA: $28.25▼

$31.50

52-Week Range

$18.02

Now: $26.10▼

$44.30

Volume477,575 shs

Average Volume304,782 shs

Market Capitalization$1.30 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.57

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Tricida has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.33, Tricida has a potential upside of 89.0% from its current price of $26.10.
Amount of Analyst Coverage
Tricida has received no research coverage in the past 90 days.

1.9 Community Rank

Outperform Votes
Tricida has received 98 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tricida has received 161 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tricida has received 62.16% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote “Outperform” if you believe TCDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tricida does not currently pay a dividend.
Dividend Growth
Tricida does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tricida insiders have bought 56.77% more of their company's stock than they have sold. Specifically, they have bought $1,115,685.00 in company stock and sold $711,650.00 in company stock.
Percentage Held by Insiders
70.40% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.57% of the stock of Tricida is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Tricida are expected to grow in the coming year, from ($5.20) to ($3.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tricida is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tricida is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tricida has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.21 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TCDA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.tricida.com

Phone415-429-7800

Debt

Debt-to-Equity Ratio0.34

Current Ratio5.56

Quick Ratio5.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.32 per share

Price / Book4.91

Profitability

EPS (Most Recent Fiscal Year)($3.72)

Net Income$-176,810,000.00

Net MarginsN/A

Return on Equity-76.03%

Return on Assets-57.35%

Miscellaneous

Employees76

Outstanding Shares49,952,000

Market Cap$1.30 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

Tricida (NASDAQ:TCDA) Frequently Asked Questions

How has Tricida's stock been impacted by COVID-19 (Coronavirus)?

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 7.0% and is now trading at $26.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tricida?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida.

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.41) by $0.08. View Tricida's earnings history.

What price target have analysts set for TCDA?

3 brokers have issued 1-year price objectives for Tricida's stock. Their forecasts range from $48.00 to $50.00. On average, they anticipate Tricida's share price to reach $49.33 in the next twelve months. This suggests a possible upside of 89.0% from the stock's current price. View analysts' price targets for Tricida.

Has Tricida been receiving favorable news coverage?

News stories about TCDA stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutTricida.

Who are some of Tricida's key competitors?

Some companies that are related to Tricida include Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), PPD (SDGR), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC) and ChemoCentryx (CCXI). View all competitors.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Who are Tricida's key executives?

Tricida's management team includes the following people:

Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
Steffen Pietzke, VP of Fin. & Chief Accounting Officer
Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (7.51%), BlackRock Inc. (5.48%), Redmile Group LLC (4.26%), JPMorgan Chase & Co. (3.01%), Cormorant Asset Management LP (1.76%) and Vivo Capital LLC (1.05%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View institutional ownership trends for Tricida.

Which major investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Driehaus Capital Management LLC, Cormorant Asset Management LP, Deutsche Bank AG, State Street Corp, International Biotechnology Trust PLC, Morgan Stanley, and Redmile Group LLC. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl. View insider buying and selling activity for Tricida.

Which major investors are buying Tricida stock?

TCDA stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, New York State Common Retirement Fund, Burrage Capital Management LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, and Alyeska Investment Group L.P.. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal, and Steffen Pietzke. View insider buying and selling activity for Tricida.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $26.10.

How big of a company is Tricida?

Tricida has a market capitalization of $1.30 billion. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff